Get the Stockscreener App
762.33
3.01%
22.26
After Hours:
761.50
-0.83
-0.11%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $762.33, with a volume of 4.86M.
It is up +3.01% in the last 24 hours and down -1.75% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$740.07
Open:
$746.82
24h Volume:
4.86M
Relative Volume:
1.27
Market Cap:
$722.49B
Revenue:
$49.00B
Net Income/Loss:
$11.11B
P/E Ratio:
62.03
EPS:
12.29
Net Cash Flow:
$-1.27B
1W Performance:
-6.20%
1M Performance:
-1.75%
6M Performance:
-6.01%
1Y Performance:
-8.42%
1-Day Range:
$745.99
$768.00
1-Week Range:
$735.44
$820.22
52-Week Range:
$677.09
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
762.33 | 664.39B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
167.33 | 396.75B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
195.22 | 333.89B | 58.33B | 3.76B | 15.39B | 2.10 |
|
NVS
Novartis Ag Adr
|
115.30 | 220.18B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
79.29 | 196.16B | 63.62B | 16.41B | 17.04B | 6.49 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
The GLP-1 Gold Rush: Assessing the Financial Implications of Expanded Medicaid and Medicare Coverage for Eli Lilly and Novo Nordisk - AInvest
Why Eli Lilly Stock Topped the Market Today - The Motley Fool
Why Novo Nordisk Stock Bumped Higher on Friday - The Motley Fool
Here’s Why Eli Lilly And Novo Nordisk Stocks Are Rallying Today - Stocktwits
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and AbbVie (ABBV) - The Globe and Mail
Lilly, Novo rally after report of Medicare weight loss coverage - TipRanks
U.S. Medicare plans to cover Eli Lilly and Co and Novo-Nordisk A/S GLP-1 weight loss drugs, with a pilot program set to begin in 2026. - 富途牛牛
Positive Outlook for Eli Lilly & Co. Amid Key Trial Outcomes and Earnings Projections - TipRanks
Eli Lilly price breaches upward correctional trend lineForecast today01-08-2025 - Economies.com
Eli Lilly: The Worst May Be Already Over (Earnings Preview) (NYSE:LLY) - Seeking Alpha
Eli Lilly (LLY) Stock Rises on Medicare Weight Loss Drug Coverage Plan - GuruFocus
Exxon Mobil, Eli Lilly, Moderna - TradingView
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued? - Morningstar
Eli Lilly and Company’s Mounjaro Displayed Cardiovascular Protection in New Head-to-Head Trial - PharmExec
Eli Lilly (LLY) Bulls Prepare for Multiyear Upside - TipRanks
Eli Lilly and Company (LLY): We Sold Some Lilly, Says Jim Cramer - Insider Monkey
Mounjaro appears more heart protective than Trulicity in trial of Eli Lilly diabetes drugs - Reuters
Eli Lilly (LLY) Reveals Promising Diabetes and Alzheimer's Trials Results - simplywall.st
Trial Finds Eli Lilly’s (LLY) Diabetes Drug Mounjaro Has Heart Health Benefits - TipRanks
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Lilly’s Mounjaro as Effective on Heart Risks as Older Drug - Bloomberg
What Makes Eli Lilly and Company (LLY) a Lucrative Investment? - Insider Monkey
Lilly’s Mounjaro shows cardiovascular benefits in diabetes study - Investing.com
Lilly’s Mounjaro shows cardiovascular benefits in diabetes study By Investing.com - Investing.com India
Mounjaro proves more heart protective than Trulicity in trial of Eli Lilly diabetes drugs - Reuters
Eli Lilly’s diabetes drug Mounjaro matches heart benefit of older treatment - statnews.com
Eli Lilly’s stock drops as Trump targets 17 drug makers with letters on their pricing - MarketWatch
Extension trial demonstrates long-term benefit for Lilly Alzheimer’s drug - European Pharmaceutical Review
Eli Lilly and Company (LLY): Jim Cramer’s “Bullish” On News Of Tariffs - Insider Monkey
Eli Lilly Stock (LLY) Will Benefit from ‘Onshoring Boom,’ Says BMO Capital Markets - TipRanks
Eisai/Biogen, Eli Lilly highlight long-term data backing Alzheimer’s drugs - Seeking Alpha
Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease - Eli Lilly and Company
Dermatology Conditions, Information & Resources - Eli Lilly
Eli Lilly Pulls Ahead In Weight-Loss Drug Race - Finimize
Novo Nordisk's stock plummets 21% as Eli Lilly faces market fluctuations in KoreaCHOSUNBIZ - Chosunbiz
Fat jab wars wipe £70bn off Ozempic maker Novo Nordisk as it feels the heat from rival Eli Lilly - MSN
Eli Lilly's CEO Pay and Its Implications for Pharma Innovation and Shareholder Value - AInvest
Assessing Eli Lilly's CEO Pay Surge: Innovation-Driven Growth and Shareholder Value Alignment - AInvest
Why Eli Lilly Stock Was Looking Sickly Today - AOL.com
Eli Lilly (LLY) Stock Dips on Novo Nordisk Guidance Update - GuruFocus
Lilly set for strong quarter after Novo profit warning - Reuters
Lilly’s Jaypirca Threatens Imbruvica’s CLL Position After Phase III Results - insights.citeline.com
Why Eli Lilly (LLY) Stock Is Falling Today - Yahoo Finance
UnitedHealth, Eli Lilly Lead Market Cap Stock Movers on Tuesday By Investing.com - Investing.com India
UnitedHealth, Eli Lilly Lead Market Cap Stock Movers on Tuesday - Investing.com
Eli Lilly (LLY) Announces Positive Results For Jaypirca In Phase 3 Trial - Yahoo Finance
Eli Lilly strikes again in weight-loss drugs fight - Life Sciences Intellectual Property Review
What's Going On With Eli Lilly Stock On Tuesday? - inkl
Eli Lilly’s New Study on LY4088044: What Investors Need to Know - TipRanks
Eli Lilly (LLY) Maintains Strong Outlook Amid Competitor's Guidance Update - GuruFocus
JPMorgan does not see Lilly read-through from Novo cut - TipRanks
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):